Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

1Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorf, T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17: 479-505. doi: 10.6004/ jnccn.2019.0023 Mohler JL Antonarakis ES Armstrong AJ D’Amico AV Davis BJ T Dorf et al Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2019 17 479 505 10.6004/jnccn.2019.002331085757Open DOISearch in Google Scholar

2Leitlinienprogramm Onkologie, S3-Leitlinie Prostatakarzinom, Version 5.1, 05/2019. [Internet]. [cited 2022 Jan 14]. Available at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_0/LL_Prostatakarzinom_Langversion_5.1.pdf Leitlinienprogramm Onkologie, S3-Leitlinie Prostatakarzinom, Version 5.1, 05/2019. [Internet] [cited 2022 Jan 14]. Available at https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_0/LL_Prostatakarzinom_Langversion_5.1.pdfSearch in Google Scholar

3Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34. doi: 10.3322/caac.21551. Siegel RL Miller KD Jemal A Cancer statistics, 2019 CA Cancer J Clin 2019 69 7 34 10.3322/caac.2155130620402Open DOISearch in Google Scholar

4Seattle cancer alliance - treating high-risk or recurrent prostate cancer. [Internet]. [cited 2020 Apr 18]. Available at: https://www.seattlecca.org/diseases/prostate-cancer/treatment-options/treating-high-risk-or- recurrent-prostate-cancer. Seattle cancer alliance - treating high-risk or recurrent prostate cancer. [Internet]. [cited 2020 Apr 18] Available at https://www.seattlecca.org/diseases/prostate-cancer/treatment-options/treating-high-risk-or-recurrent-prostate-cancer.Search in Google Scholar

5Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403. doi: 10.1016/j.ejca.2012.12.027 Ferlay J Steliarova-Foucher E Lortet-Tieulent J Rosso S Coebergh JWW Comber H et al Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 2013 49 1374 403 10.1016/j.ejca.2012.12.02723485231Open DOISearch in Google Scholar

6Statistisches Bundesamt - Sterbefälle durch Krebs insgesamt 2019. [Internet]. [cited 2021 Apr 25]. Available at: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/sterbefaelle-krebs-insgesamt.html Statistisches Bundesamt - Sterbefälle durch Krebs insgesamt 2019 [Internet]. [cited 2021 Apr 25]. Available at https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/sterbefaelle-krebs-insgesamt.htmlSearch in Google Scholar

7Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-24. doi: 10.1056/ NEJMoa1606220 Hamdy FC Donovan JL Lane JA Mason M Metcalfe C Holding P et al 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer N Engl J Med 2016 375 1415 24 10.1056/NEJMoa160622027626136Open DOISearch in Google Scholar

8Renfer LG, Schow D, Thompson IM, Optenberg S. Is ultrasound guidance necessary for transrectal prostate biopsy? J Urol 1995; 154: 1390-1. PMID: 7658544 Renfer LG Schow D Thompson IM Optenberg S Is ultrasound guidance necessary for transrectal prostate biopsy? J Urol 1995 154 1390 1 PMID: 765854410.1016/S0022-5347(01)66873-3Search in Google Scholar

9Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004; 171: 2122-7. doi: 10.1097/01.ju.0000123981.03084.06 Abuzallouf S Dayes I Lukka H Baseline staging of newly diagnosed prostate cancer: a summary of the literature J Urol 2004 171 2122 7 10.1097/01.ju.0000123981.03084.0615126770Open DOISearch in Google Scholar

10Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 2015; 68: 1045-53. doi: 10.1016/j.eururo.2015.01.013 Fütterer JJ Briganti A De Visschere P Emberton M Giannarini G Kirkham A et al Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature Eur Urol 2015 68 1045 53 10.1016/j.eururo.2015.01.01325656808Open DOISearch in Google Scholar

11Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70: 926-37. doi: 10.1016/j.eururo.2016.06.021 Perera M Papa N Christidis D Wetherell D Hofman MS Murphy DG et al Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis Eur Urol 2016 70 926 37 10.1016/j.eururo.2016.06.02127363387Open DOISearch in Google Scholar

12Wachter S, Gerstner N, Goldner G, Dieckmann K, Colotto A, Pötter R. Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: early results. Strahlenther Onkol 1997; 175(Suppl. 2): 84-6. doi: 10.1007/BF03038898. Wachter S Gerstner N Goldner G Dieckmann K Colotto A Pötter R Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: early results Strahlenther Onkol 1997 175Suppl. 2 84 6 10.1007/BF0303889810394407Open DOISearch in Google Scholar

13Sharfo AWM, Dirkx MLP, Bijman RG, Schillemans W, Breedveld S, Aluwini S, et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiother Oncol 2018; 128: 349-56. doi: 10.1016/j.radonc.2018.05.028 Sharfo AWM Dirkx MLP Bijman RG Schillemans W Breedveld S Aluwini S et al Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning Radiother Oncol 2018 128 349 56 10.1016/j.radonc.2018.05.02829885745Open DOISearch in Google Scholar

14Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/ external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33. doi: 10.1016/s0360-3016(03)00784-3. Kupelian PA Potters L Khuntia D Ciezki JP Reddy CA Reuther AM et al Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/ external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 2004 58 25 33 10.1016/s0360-3016(03)00784-314697417Open DOISearch in Google Scholar

15Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a Phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys 2019; 104: 790-7. doi: 10.1016/j.ijrobp.2019.02.045 Pasalic D Kuban DA Allen PK Tang C Mesko SM Grant SR et al Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a Phase 3, single institution randomized clinical trial Int J Radiat Oncol Biol Phys 2019 104 790 7 10.1016/j.ijrobp.2019.02.045657968430836166Open DOISearch in Google Scholar

16Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87. doi: 10.1016/S1470-2045(07)70143-2 Dearnaley DP Sydes MR Graham JD Aird EG Bottomley D Cowan RA et al Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 2007 8 475 87 10.1016/S1470-2045(07)70143-217482880Open DOISearch in Google Scholar

17Peeters STH, Heemsbergen WD, Koper PCM, Van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-6. doi: 10.1200/JCO.2005.05.2530 Peeters STH Heemsbergen WD Koper PCM Van Putten WLJ Slot A Dielwart MFH et al Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 2006 24 1990 6 10.1200/JCO.2005.05.253016648499Open DOISearch in Google Scholar

18Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized Phase III trial. Eur Urol 2018; 74: 432-41. doi: 10.1016/j.eururo.2018.06.018 Nabid A Carrier N Martin AG Bahary JP Lemaire C Vass S et al Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized Phase III trial Eur Urol 2018 74 432 41 10.1016/j.eururo.2018.06.01829980331Open DOISearch in Google Scholar

19Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediateterm androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3. Lancet Oncol 2019; 20: 267-81. doi: 10.1016/S1470-2045(18)30757-5 Denham JW Joseph D Lamb DS Spry NA Duchesne G Matthews J et al Short-term androgen suppression and radiotherapy versus intermediateterm androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3 Lancet Oncol 2019 20 267 81 10.1016/S1470-2045(18)30757-530579763Open DOISearch in Google Scholar

20Bolla M, De Reijke TM, Van Tienhoven G, Van Den Bergh ACM, Oddens J, Poortmans PMP, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27. doi: 10.1056/ NEJMoa0810095 Bolla M De Reijke TM Van Tienhoven G Van Den Bergh ACM Oddens J Poortmans PMP et al Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 2009 360 2516 27 10.1056/NEJMoa081009519516032Open DOISearch in Google Scholar

21Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-11. doi: 10.1016/S0140-6736(11)61095-7 Warde P Mason M Ding K Kirkbride P Brundage M Cowan R et al Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 2011 378 2104 11 10.1016/S0140-6736(11)61095-7324393222056152Open DOISearch in Google Scholar

22Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 2009; 115: 3446-56. doi: 10.1002/cncr.24392 Bria E Cuppone F Giannarelli D Milella M Ruggeri EM Sperduti I et al Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials Cancer 2009 115 3446 56 10.1002/cncr.2439219484790Open DOISearch in Google Scholar

23Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-73. doi: 10.1016/S1470-2045(10)70223-0 Bolla M Van Tienhoven G Warde P Dubois JB Mirimanoff RO Storme G et al External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 2010 11 1066 73 10.1016/S1470-2045(10)70223-020933466Open DOISearch in Google Scholar

24ICRU Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). [Internet]. Bethesda: International Commission on Radiation Units and Measurements; 1999. [cited 2020 Apr 18]. Available at: http://www.mendeley.com/catalog/prescribing-recording-reporting-photon-beam-therapy-report-62/ ICRU Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). [Internet]. Bethesda: International Commission on Radiation Units and Measurements; 1999. [cited 2020 Apr 18] Available at http://www.mendeley.com/catalog/prescribing-recording-reporting-photon-beam-therapy-report-62/Search in Google Scholar

25Wachter S, Gerstner N, Dorner D, Goldner G, Colotto A, Wambersie A, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 91-100. doi: 10.1016/s0360-3016(01)01821-1 Wachter S Gerstner N Dorner D Goldner G Colotto A Wambersie A et al The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 2002 52 91 100 10.1016/s0360-3016(01)01821-111777626Open DOISearch in Google Scholar

26Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74. doi: 10.1016/j.ijrobp.2006.04.029 Roach M Hanks G Thames H Schellhammer P Shipley WU Sokol GH et al Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 2006 65 965 74 10.1016/j.ijrobp.2006.04.02916798415Open DOISearch in Google Scholar

27Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol 1995; 31: 1341-6. doi: 10.1016/0360-3016(95)00060-C Cox JD Stetz J Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol 1995 31 1341 6 10.1016/0360-3016(95)00060-C7713792Open DOISearch in Google Scholar

28Ozyigit G, Onal C, Igdem S, Alicikus ZA, Iribas A, Akin M, et al. Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy: TROD 09-001 multi-institutional study. Strahlentherapie und Onkol 2019; 195: 882-93. doi: 10.1007/s00066-019-01476-z Ozyigit G Onal C Igdem S Alicikus ZA Iribas A Akin M et al Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy: TROD 09-001 multi-institutional study Strahlentherapie und Onkol 2019 195 882 93 10.1007/s00066-019-01476-z31143994Open DOISearch in Google Scholar

29Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One 2016; 11: 1-17. doi: 10.1371/journal.pone.0154499. Yu T Zhang Q Zheng T Shi H Liu Y Feng S et al The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures PLoS One 2016 11 1 17 10.1371/journal.pone.0154499486513827171271Open DOISearch in Google Scholar

30Dearnaley D, Griffin CL, Lewis R, Mayles P, Mayles H, Naismith OF, et al. Toxicity and patient-reported outcomes of a Phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). Int J Radiat Oncol Biol Phys 2019; 103: 605-17. doi: 10.1016/j.ijrobp.2018.10.003 Dearnaley D Griffin CL Lewis R Mayles P Mayles H Naismith OF et al Toxicity and patient-reported outcomes of a Phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL) Int J Radiat Oncol Biol Phys 2019 103 605 17 10.1016/j.ijrobp.2018.10.003636176830528653Open DOISearch in Google Scholar

31Rammant E, Ost P, Swimberghe M, Vanderstraeten B, Lumen N, Decaestecker K, et al. Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial. Strahlenther Onkol 2019; 195: 393-401. doi: 10.1007/s00066-018-1395-y Rammant E Ost P Swimberghe M Vanderstraeten B Lumen N Decaestecker K et al Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial Strahlenther Onkol 2019 195 393 401 10.1007/s00066-018-1395-y30406289Open DOISearch in Google Scholar

32Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized Phase III trial. J Clin Oncol 2021; 39: 787-96. doi: 10.1200/JCO.20.02873 Kerkmeijer LGW Groen VH Pos FJ Haustermans K Monninkhof EM Smeenk RJ et al Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized Phase III trial J Clin Oncol 2021 39 787 96 10.1200/JCO.20.0287333471548Open DOISearch in Google Scholar